Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market Implications of the EU Commission's Sector Inquiry from an IP, Competition Law and Economic Perspective

This book discusses the implications of the 2009 EU Commission's Pharmaceutical Sector Inquiry on originator's opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Philipp, Marc P. (auth)
Formaat: Elektronisch Hoofdstuk
Taal:Engels
Gepubliceerd in: Nomos Verlagsgesellschaft mbH & Co. KG 2011
Reeks:Munich Intellectual Property Law Center - MIPLC
Onderwerpen:
Online toegang:DOAB: download the publication
DOAB: description of the publication
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_50417
005 20210211
003 oapen
006 m o d
007 cr|mn|---annan
008 20210211s2011 xx |||||o ||| 0|eng d
020 |a /dx.doi.org/10.5771/9783845231037 
020 |a 9783845231037 
040 |a oapen  |c oapen 
024 7 |a http://dx.doi.org/10.5771/9783845231037  |c doi 
041 0 |a eng 
042 |a dc 
100 1 |a Philipp, Marc P.  |4 auth 
245 1 0 |a Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market  |b Implications of the EU Commission's Sector Inquiry from an IP, Competition Law and Economic Perspective 
260 |b Nomos Verlagsgesellschaft mbH & Co. KG  |c 2011 
300 |a 1 electronic resource (92 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Munich Intellectual Property Law Center - MIPLC 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a This book discusses the implications of the 2009 EU Commission's Pharmaceutical Sector Inquiry on originator's opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator's ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry's final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry's findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
653 |a Wettbewerbsrecht 
653 |a Handels- und Wirtschaftsrecht 
653 |a Kartellrecht 
856 4 0 |a www.oapen.org  |u https://www.nomos-elibrary.de/10.5771/9783845231037  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/50417  |7 0  |z DOAB: description of the publication